Nalaganje...
Developing EZH2 Targeted Therapy for Lung Cancer
Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown anti-tumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinomas models expressing high levels of EZH2 (1).
Shranjeno v:
| izdano v: | Cancer Discov |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5012289/ https://ncbi.nlm.nih.gov/pubmed/27587466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0800 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|